a developer and marketer of prescription pharmaceutical products for the treatment of gastrointestinal diseases, is recently down $2.51 to $9.01. Weakness was attributable to concerns of Colazal generic competition. SLXP call option volume of 9,940 contracts compares to put volume of 8,890 contracts. SLXP January option implied volatility of 104 is above its 26-week average of 70 according to Track Data, suggesting larger risk.